Potential Changes for MRD in the Future

While artificial intelligence (AI) holds promise to improve the diagnosis of melanoma, researchers of a new review outlined challenges with these novel approaches.

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients with hemophilia A or B.

Rucaparib maintenance improved progression-free survival (PFS) in homologous recombination deficiency (HRD)-negative advanced ovarian cancer, irrespective of baseline prognostic factors.